AstraZeneca stock price forecast: Global initiatives power AZN up 3.04% amid bullish signals

Traders Union
All News
Financial News
AstraZeneca jumps 3.04% to GBX 13,964

Highlights

AstraZeneca began trading ordinary shares on the New York Stock Exchange under ticker 'AZN', streamlining investor access and replacing its previous ADS program.
The company secured exclusive rights to CSPC Pharmaceutical’s experimental obesity drugs in a deal worth up to $18.5 billion, expanding its obesity treatment portfolio.
AZN trades at GBX 13,964, above the MA-20 and MA-50, with technical signals indicating an 80% probability of a further rise toward GBX 14,300.

Obesity drug deal and NYSE debut accelerate AstraZeneca’s global expansion

AstraZeneca expanded its global market presence by beginning ordinary share trading on the New York Stock Exchange under the ticker symbol 'AZN', simplifying investor access and replacing its former ADS program. In parallel, the company secured exclusive development and commercialization rights to CSPC Pharmaceutical’s experimental obesity drugs in a deal valued up to $18.5 billion, substantially increasing its reach in the obesity treatment segment. AstraZeneca also committed multibillion-dollar investments into China for drug discovery, development, and manufacturing, demonstrating its continued portfolio growth and international expansion.

Mixed momentum signals as technical breakout meets resistance reshuffle

The current AZN price at GBX 13,964 stands above the MA-20 (GBX 13,834.40), MA-50 (GBX 13,757.92), and is well above the long-term MA-200 (GBX 11,937.13). This structure suggests a rebound in the short- and medium-term and confirms preserved support on longer timeframes. The nearest dynamic resistance is the Ichimoku Kijun at GBX 13,839, which has recently been breached, turning this level into a potential new short-term support zone.

Momentum signals on the daily chart show some mixed signals. The MACD remains in negative territory and forecasts “Sell,” pointing to cautious momentum, but the ADX is moderately strong and forecasts “Buy,” suggesting that trend strength is reviving. RSI is under 50 and gives a Sell signal, while Stochastic RSI is in “Strong Buy” territory, highlighting recent upward pressure but also potential oscillation as CCI leans negative. Bull/Bear Power is classified as “Oversold” with a significant negative value, signaling that while sellers have dominated intraday, the situation may be turning as price nears the daily high. Awesome Oscillator aligns with the underlying caution, forecasting "Sell" and matching MACD’s warning. There was a slight upward gap from the previous close (GBX 13,552) to today’s open (GBX 13,584), and with a daily gain of 3.04% and the current price trading right near the day’s high, intraday volatility has been elevated. The overall intraday tone reflects persistent strength pushing into the upper end of today’s range despite some momentum divergence.

Bullish range forecast as momentum underpins consolidation risk

For the next five trading days, the expected trading range is GBX 13,600 – 14,300. The probability of further price increase is high (80%), while a decline is less likely. The baseline scenario assumes consolidation within this volatility band, holding above the MA-20 and Ichimoku Kijun. Bullish extension may target GBX 14,300 or higher if buying momentum holds, but a drop below GBX 13,800 could trigger downside risk toward GBX 13,600.

Viktoras Karapetjanc, expert at Traders Union, sees AstraZeneca in a constructive position after its NYSE listing and deal in the obesity drug segment. He believes macro expansion and robust support above key moving averages reflect growing investor confidence. Fundamentals are strong, and global strategy signals long-term credibility. Short-term momentum remains mixed, but the technical structure and recent news support a bullish bias. "With AstraZeneca holding above major supports and expanding globally, I expect buyers to push for GBX 14,300 if levels above MA-20 and Kijun are defended."

Previously it was reported that AstraZeneca PLC is trading below its short- and medium-term moving averages, signaling ongoing selling pressure despite maintaining a bullish long-term trend above key support levels. Technical momentum remains mixed, with conflicting signals from RSI, Stochastic, and MACD, while price action is consolidating within a broad range, and an upside breakout above resistance could trigger further gains.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.